Dual Cholesterol Measures May Improve Heart Risk Prediction
Medscape
Last updated: May 20, 2026
Elevated levels of non-high-density lipoprotein (non-HDL) cholesterol and apolipoprotein B (ApoB) are significantly linked to a higher risk of atherosclerotic cardiovascular disease (ASCVD) and myocarditis. This association holds true across various clinical settings and regardless of diabetes status. ApoB, in particular, emerges as a stronger predictor of ASCVD risk than non-HDL cholesterol.
- The study analyzed data from over 1.9 million individuals across 37 prospective cohort studies, examining the relationship between non-HDL cholesterol, ApoB, and cardiovascular events.
- Results indicated a consistent association between higher non-HDL cholesterol and increased ASCVD risk, even at levels below current treatment thresholds.
- ApoB demonstrated a stronger correlation with ASCVD risk compared to non-HDL cholesterol, suggesting its potential as a more precise risk marker.
- The association between these lipid markers and ASCVD remained evident even in individuals without diabetes, highlighting their broad applicability in risk assessment.
- Furthermore, both high non-HDL cholesterol and ApoB were linked to an elevated risk of myocarditis.
- The findings suggest that targeting ApoB could be a more effective strategy for reducing ASCVD risk than solely focusing on non-HDL cholesterol.
- These insights reinforce the importance of comprehensive lipid profiling in cardiovascular risk stratification and management.
